Spinnaker Trust’s Novartis NVS Stock Holding History

Spinnaker Trust’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$299K	Hold	1,959	–	–	0.02%	250
2025 Q4	$270K	Hold	1,959	–	–	0.01%	266
2025 Q3	$251K	Hold	1,959	–	–	0.01%	268
2025 Q2	$237K	Buy	+1,959	New	+$221K	0.01%	271
2024 Q4	–	Sell	-1,759	Closed	-$202K	–	289
2024 Q3	$202K	Buy	+1,759	New	+$200K	0.01%	280
2023 Q4	–	Sell	-2,059	Closed	-$210K	–	275
2023 Q3	$210K	Hold	2,059	–	–	0.02%	262
2023 Q2	$208K	Buy	+2,059	New	+$206K	0.02%	253
2023 Q1	–	Sell	-4,504	Closed	-$408K	–	263
2022 Q4	$408K	Sell	4,504 -216	-5%	-$18.2K	0.03%	190
2022 Q3	$359K	Hold	4,720	–	–	0.03%	205
2022 Q2	$399K	Buy	4,720 +334	+8%	+$29.3K	0.03%	205
2022 Q1	$385K	Sell	4,386 -475	-10%	-$41.1K	0.03%	211
2021 Q4	$426K	Hold	4,861	–	–	0.03%	209
2021 Q3	$398K	Hold	4,861	–	–	0.03%	207
2021 Q2	$443K	Sell	4,861 -200	-4%	-$17.8K	0.03%	196
2021 Q1	$432K	Buy	5,061 +692	+16%	+$62.1K	0.03%	181
2020 Q4	$411K	Hold	4,369	–	–	0.03%	180
2020 Q3	$379K	Hold	4,369	–	–	0.03%	172
2020 Q2	$381K	Buy	4,369 +156	+4%	+$13.5K	0.04%	170
2020 Q1	$347K	Buy	4,213 +670	+19%	+$59.8K	0.04%	179
2019 Q4	$335K	Sell	3,543 -710	-17%	-$63.7K	0.03%	203
2019 Q3	$369K	Buy	4,253 +515	+14%	+$46.2K	0.04%	191
2019 Q2	$340K	Sell	3,738 -664	-15%	-$56.2K	0.03%	190
2019 Q1	$378K	Hold	4,402	–	–	0.04%	181
2018 Q4	$338K	Hold	4,402	–	–	0.04%	175
2018 Q3	$339K	Buy	4,402 +1,207	+38%	+$89.2K	0.03%	182
2018 Q2	$215K	Buy	3,195 +16	+0.5%	+$1.1K	0.02%	207
2018 Q1	$229K	Sell	3,179 -110	-3%	-$8.37K	0.02%	199
2017 Q4	$247K	Hold	3,289	–	–	0.03%	196
2017 Q3	$252K	Hold	3,289	–	–	0.03%	180
2017 Q2	$246K	Hold	3,289	–	–	0.03%	181
2017 Q1	$219K	Sell	3,289 -8,887	-73%	-$592K	0.03%	193
2016 Q4	$795K	Sell	12,176 -2,111	-15%	-$137K	0.11%	103
2016 Q3	$1.01M	Buy	14,287 +165	+1%	+$12K	0.14%	98
2016 Q2	$1.04M	Buy	14,122 +8,517	+152%	+$588K	0.14%	99
2016 Q1	$364K	Hold	5,605	–	–	0.05%	154
2015 Q4	$432K	Hold	5,605	–	–	0.06%	146
2015 Q3	$462K	Hold	5,605	–	–	0.07%	141
2015 Q2	$494K	Buy	5,605 +154	+3%	+$14.1K	0.07%	139
2015 Q1	$482K	Buy	5,451 +340	+7%	+$30.2K	0.07%	139
2014 Q4	$424K	Buy	5,111 +480	+10%	+$39.8K	0.06%	141
2014 Q3	$391K	Sell	4,631 -1,814	-28%	-$147K	0.06%	147
2014 Q2	$523K	Sell	6,445 -4,145	-39%	-$326K	0.09%	121
2014 Q1	$807K	Hold	10,590	–	–	0.13%	98
2013 Q4	$762K	Sell	10,590 -78	-0.7%	-$5.42K	0.13%	97
2013 Q3	$733K	Hold	10,668	–	–	0.13%	95
2013 Q2	$676K	Buy	+10,668	New	+$694K	0.13%	97

Other funds holding NVS

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Spinnaker Trust's NVS Position: Q1 2026 in Review

Spinnaker Trust held its Novartis (NVS) position steady in Q1 2026 at 1,959 shares worth $299K. The position accounts for 0.02% of the portfolio, ranked #250.

Spinnaker Trust first reported a position in NVS in Q2 2013 and has held it in 46 quarters since. The position peaked at $1.04M in Q2 2016. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

Spinnaker Trust held 1,959 shares of Novartis worth $299K as of Q1 2026.
Spinnaker Trust left its Novartis share count unchanged in Q1 2026.
Novartis made up 0.02% of Spinnaker Trust's portfolio in Q1 2026, its #250 holding.
Spinnaker Trust first reported a position in Novartis in Q2 2013 and has held it in 46 quarters since.
Spinnaker Trust's Novartis position peaked at $1.04M in Q2 2016.
1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Spinnaker Trust's 13F filing for Q1 2026, filed 23 Apr 2026.